Multiple myeloma: a retrospective analysis of clinical outcomes based on the patient registry of the Moscow City Clinical Hospital No. 52 (2022–2025)
Authors:
- Elena N. MisyurinaEMElena N. Misyurina
- E. N. ZotinaEZE. N. Zotina
- S. M. GadzhievaSGS. M. Gadzhieva
- N. G. ChernovaNCN. G. Chernova
- E. A. KarimovaEKE. A. Karimova
- E. I. ZhelnovaEZE. I. Zhelnova
- E. A. BaryakhEBE. A. Baryakh
- A. B. MakeshovaAMA. B. Makeshova
- D. S. MaryinDMD. S. Maryin
- O. D. ZakharovOZO. D. Zakharov
- T. N. TolstykhTTT. N. Tolstykh
- V. N. YakimetsVYV. N. Yakimets
Open Access
- 10 December 2025
- journal article
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 41-50
Abstract
Background. Multiple myeloma (MM) is the second most common oncohematological disease among malignant tumors of the hematopoietic and lymphoid tissues. According to epidemiological data, MM accounts for approximately 10–12 % of all hematological malignancies. An analysis of the main clinical parameters and treatment outcomes was conducted in patients with MM included in the registry of the Moscow Clinical Research Center “Hospital 52” in 2022–2025. Aim. To evaluate the clinical and hematological profile of MM patients, as well as to analyze the effectiveness of first-line antitumor therapy, including standard treatment regimens and high-dose chemotherapy programs followed by autologous hematopoietic stem cell transplantation. Materials and methods. The observational retrospective study included 325 patients with newly diagnosed MM: 147 (45.2 %) men, 178 (54.8 %) women. The median age at diagnosis was 67 (22–92) years. The number of patients aged 65 years and older was 194 (59.7 %). Antitumor therapy was carried out according to current clinical guidelines. In the first line of therapy, bortezomib was most often used, in the second – lenalidomide and monoclonal antibodies, in the third – monoclonal antibodies. Results. According to the International Staging System, 62.2 % of patients had stage III disease. Myeloma nephropathy was detected in 28.9 % of patients, with 20.3 % requiring programmed dialysis. Autologous hematopoietic stem cell transplantation was performed in 30.8 % of patients. Response to induction therapy: complete remission – 8.0 %; very good partial remission – 27.7 %; partial remission – 24.6 %. The best response rates were achieved with the use of monoclonal antibodies (66.6 % – complete remission + very good partial remission). With a median follow-up of 12.6 months, 1-year overall survival was 83.9 % (95 % confidence interval 82.3–85.4), 1-year progression-free survival was 75.8 % (95 % confidence interval 73.9–77.6). Conclusion. Using registry data allows us to characterize the MM patient population, evaluate the effectiveness of patient treatment, plan the work of the hematology center, forecast the funds required for the purchase of medications, and improve the organizational aspects of the hematology service in a multidisciplinary institution.Keywords
This publication has 25 references indexed in Scilit:
- Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2024
- Time from first symptom onset to the final diagnosis of multiple myeloma (MM) – possible risks and future solutions: retrospective and prospective ‘Deutsche Studiengruppe MM’ (DSMM) and ‘European Myeloma Network’ (EMN) analysisLeukemia & Lymphoma, 2019
- Global Burden of Multiple MyelomaJAMA Oncology, 2018
- Multiple myelomaNature Reviews Disease Primers, 2017
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014
- Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based studyThe Lancet Oncology, 2014
- Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsBlood, 2011
- Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centreNephrology Dialysis Transplantation, 2009
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975